MANAGEMENT OF PATIENT WITH ARTERIAL FIBRILLATION: WHAT`S NEW?
https://doi.org/10.15829/1560-4071-2016-12-97-102
Abstract
The literary review consists of two parts. The first takes into consideration the renewed European guidelines of 2016 for atrial fibrillation patients management. The accent is made on the renewed approaches for anticoagulation treatment regardless the gender, on new points in the risks of haemorrhagic complications, renewed schemes of double and triple antithrombotic therapy after the percutaneous intervention and/or acute coronary syndrome and approaches for the restarting of anticoagulation after ischemic stroke. The second part focuses on the real clinical practice including three latest publications, which consider the safety of warfarin, dabigatran and rivaroxaban in patients with atrial fibrillation of non-valvular aetiology by the data from insurance companies. Based on the data provided, there is a conclusion on the benefit of dabigatran for more safety in all recommended dosages.
About the Authors
D. A. Napalkov
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. A. Sokolova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2016; doi: 10.1093/eurheartj/ehw210.
2. Gorst-Rasmussen A, Lip GYH, Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepid Drug Saf 2016; doi: 10.1002/pds.4034.
3. Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016; 19; 116 (5).
4. Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs. 2016; Sep 14.
5. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016 Oct 3. doi: 10.1001/ jamainternmed.2016.5954.
Review
For citations:
Napalkov D.A., Sokolova A.A. MANAGEMENT OF PATIENT WITH ARTERIAL FIBRILLATION: WHAT`S NEW? Russian Journal of Cardiology. 2016;(12):97-102. (In Russ.) https://doi.org/10.15829/1560-4071-2016-12-97-102
Views:
1507
Email this article 